

REPLIGEN CORP
Form 8-K
April 11, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 9, 2012

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-14656
(Commission
File Number)

04-2729386
(IRS Employer
Identification No.)

Edgar Filing: REPLIGEN CORP - Form 8-K

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA

(Address of principal executive offices)

Registrant's telephone number, including area code (781) 250-0111

02453

(Zip Code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) Election of Michael A. Griffith to the Board of Directors.

On April 9, 2012, Repligen Corporation (the Company) increased the size of its Board of Directors from seven to eight members and appointed Michael A. Griffith as a director of the Company. Mr. Griffith is currently CEO and director at Laureate Biopharma. For his services as a director of the Company, Mr. Griffith will be compensated consistent with the Company's current non-employee director compensation policy, although his initial award of an option to purchase 24,000 shares of the Company's common stock will be delayed until the Company's 2012 Annual Meeting of Stockholders. Mr. Griffith was not appointed to any committees of the Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPLIGEN CORPORATION

Dated: April 11, 2012

By: /s/ Walter C. Herlihy
Walter C. Herlihy
President and Chief Executive Officer